Nurix Therapeutics, Inc. (NRIX) reported a quarterly loss of $0.79 per share for the period ending February 2026, which exceeded analysts’ expectations of a loss of $0.76. In comparison, the company reported a loss of $0.67 per share in the same quarter the previous year. Revenue for the quarter was $6.25 million, significantly below the Zacks Consensus Estimate of $14.65 million, representing a 57.21% miss and a decline from $18.45 million year-over-year.
Over the last four quarters, Nurix has surpassed consensus EPS estimates twice. The company’s shares have declined approximately 13.8% since the start of 2023, contrasting with the S&P 500’s drop of 3.3%. The current consensus EPS estimate for the upcoming quarter is -$0.80, with projected revenues of $14.11 million.
